A body of evidence indicates that BTG1 expression is negatively correlated with tumor invasion, lymph node metastasis, the clinical stage, and/or a low survival rate in patients with various cancers. Here, BTG1 is linked to metastatic malignant neoplasm in the lymph nodes.